Hannah Slater | Authors


Safety of Pembrolizumab With Capecitabine and Bevacizumab Demonstrated in MSS mCRC

January 15, 2021

Immunotherapy with pembrolizumab in combination with capecitabine-based chemotherapy and the VEGF inhibitor bevacizumab, appeared tolerable as treatment of patients with microsatellite stable metastatic colorectal cancer, showing a safety profile that was expected with the drug, results from a phase 2 study show.

Survival Improved With Tucatinib Regimen in HER2-Positive Metastatic Breast Cancer

September 21, 2020

Statistically significant and clinically meaningful improvements in both progression-free survival and overall survival were observed with the addition of tucatinib to trastuzumab and capecitabine as treatment of patients with HER2-positive metastatic breast cancer, irrespective of the presence of brain metastases.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL

May 30, 2020

Interim analysis of the ZUMA-5 study indicates that patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor T-cell therapy of axicabtagene ciloleucel had high rates of response and demonstrated the agent's manageable safety profile.